In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-alpha alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression

Journal of B.U.ON.

Volumn 17, Issue 4, 2012, Pages 761-769

  Konjevic, Gordana ^a,b   Mirjacic Martinovic, K ^a   Vuletic, A ^a   Babovic, N ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

IFN ; Melanoma; NK cell receptors; NK cells; Retinoic acid

Indexed keywords

ALPHA INTERFERON; CD161 ANTIGEN; ISOTRETINOIN; NATURAL KILLER CELL RECEPTOR NKG2D;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MALE; METASTATIC MELANOMA; NATURAL KILLER CELL; PROTEIN EXPRESSION;

ADULT; AGED; FEMALE; GPI-LINKED PROTEINS; HUMANS; INTERFERON-ALPHA; ISOTRETINOIN; KILLER CELLS, NATURAL; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IGG;

EID: 84872419720     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Konjevic G, Mirjacic-Martinovic K, Vuletic A et al. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007; 24: 1-11. (Pubitemid 46569334)
2. Konjevic G, Jovic V, Vuletic A, Radulovic S, Jelic S, Spuzic I. CD69 on CD56 + NK cells and response to chemoimmunotherapy in metastatic melanoma. Eur J Clin Invest 2007; 37: 887-896. (Pubitemid 350029209)
3. Atkins MB. Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am 1998; 12: 877-902. (Pubitemid 28410381)
4. Rosenthal MA, Oratz R. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma. Am J Clin Oncol 1998; 21: 352-354. (Pubitemid 28366902)
5. Bremers AJ, Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 2000; 34: 1-25. (Pubitemid 30227314)
6. Kroger A, Köster M, Schroeder K, Hauser H, Mueller PP. Activities of IRF-1. J Interferon Cytokine Res 2002; 22: 5-14.
7. Pelicano L, Li F, Schindler C, Chelbi-Alix MK. Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action. Oncogene 1997; 15: 2349-2359.
8. Vertuani S, Dubrovska E, Levitsky V, Jager MJ, Kiessling R, Levitskaya J. Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells. Cancer Immunol Immunother 2007; 56: 193-204. (Pubitemid 44833093)
9. Vuletic A, Konjevic G, Milanovic D, Ruzdijic S, Jurisic V. Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bc1-2 protein levels in G0/G1 arrested HL-60 cells. Pathol Oncol Res 2010; 16: 393-401.
10. Nagler A, Lanier LL, Cwirla S. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143: 3183-3191. (Pubitemid 20010143)
11. Warren HS, Kinnear BF. Quantitative analysis of the effect of CD16 ligation on human NK cell proliferation. J Immunol 1999; 162; 735-742. (Pubitemid 29035394)
12. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22, 633-640. (Pubitemid 33043908)
13. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006; 20: 123-137. (Pubitemid 43786166)
14. Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immuno 2003; 33: 381-391. (Pubitemid 36267602)
15. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev 2006; 214: 56-72. (Pubitemid 44707902)
16. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203: 633-645.
17. Jackson A, Warner N. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedman H, Fahey J (Eds): Manual of Clinical Laboratory Immunology (3rd Edn). American Society for Microbiology, 1986, pp 226-235.
18. Konjevic G, Martinovic KM, Jurisic V, Babovic N, Spuzic I. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD 158a receptors on CD3-CD16+ NK cells. Biomarker 2009; 14: 258-270.
19. Brown RL, Ortaldo JR, Griffith RL, Blanca I, Rabin H. The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium. J Immunol Methods 1985; 81: 207-214. (Pubitemid 15013210)
20. Smyth MJ, Cretney E, Kelly JM et al. Activation of NK cell cytotoxicity. Mol Immunol 2005; 42: 501-510 (Pubitemid 39655961)
21. Konjevic G, Mirjacic Martinovic K, Vuletic A, Radenkovic S. Novel aspects of in vitro IL-2 or IFN-α enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction. BiomedPharmacother 2010; 64: 663-671.
22. Konjevic G, Mirjacic Martinovic K, Vuletic A, Babovic N. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients. Melanoma Res 2010; 20: 459-467.
23. Zhang C, Zhang J, Sun R, Feng J, Wei H, Tian Z. Opposing effect of IFNgamma and IFNalpha on expression of NKG2D receptors: negative regulation of IFNgamma on NK cells. Int Immunopharmacol 2005; 5: 1057-1067.
24. Lesinski GB, Trefry J, Brasdovich M et al. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res 2007; 13: 5010-5019. (Pubitemid 47502065)
25. Liang S, Wei H, Sun R, Tian Z. IFN alpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine 2003; 23: 190-199. (Pubitemid 38340386)
26. Critchley-Thorne RJ, Simons DL, Yan N et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A 2009; 106: 9010-9015.
27. Faus H, Haendler B. Post-translational modifications of steroid receptors. Biomed Pharmacother 2006; 60: 520-528.
28. Tassi I, Klesney-Tait J, Colonna M. Dissecting natural killer cell activation pathways through analysis of genetic mutations in human and mouse. Immunol Rev 2006; 214: 92-105. (Pubitemid 44707904)
29. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-I), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine 2003; 24: 81-90. (Pubitemid 37324035)
30. Konjevic G, Mirjacic Martinovic K, Vuletic A, Jurisic V, Spuzic I. Distribution of several activating and inhibitory receptors on CD3(-) CD16(+) NK cells and their correlation with NK cell function in healthy individuals. J Membr Biol 2009; 230: 113-123.